Leo Lens™

Pharma

Helping Protect Sight

TCA
Connect w/ SDVG

October 2020

Kenny Key

kkey@leolens.com

Problem – Ocular Drug Delivery is Antiquated and Inadequate

- Old Standard of Care
  - **Daily** Topical Eye Drop Therapy
    - **Non-Compliance**
    - Low bioavailability ~5%
    - Side effects from **chronic exposure to preservatives**

- Future Standard of Care
  - + Non-Invasive **Continuous Dosing** with Patented MediPrint™ Technology
    - + 24/7 continuous delivery from a **weekly** therapy
    - + **Preservative free**

Photo credit: https://www.glaucoma.org/treatment/eyedrop-tips.php

Solution - Proprietary MediPrint™ Process

Drug Delivery Platform for the Effective Treatment of Ocular Diseases (e.g. Glaucoma)

1. Select Drug

- Tier 1: Generic
- Tier 2: Patented
- Tier 3: Novel R&D

+

FDA Approved Contact Lens

2. Prepare MediPrint™ Ink

3. MediPrint™ on Lens Surface

4. Hydration & Packaging



5. Sterilization



Established Pipeline

Development Milestones Completed



Total: $11B+

+ Significant OUS Opportunities (Europe, Asia)

Why are we Here? – There is a Significant Unmet Need

- Helping prevent the loss of sight caused by **glaucoma**
- Glaucoma is the **2nd leading cause of blindness**
  - Non-compliance
  - Poor early diagnosis/detection
- **"Silent thief"** due to asymptomatic progression



Why a Paradigm Shift in Care is Beneficial?

Ophthalmologists (MD)

- Focus on severe patients
- Focus on surgical and laser procedures
- Frees up chair time

Mild/Moderate

Severe

Optometrists (OD)



- Often first to diagnose glaucoma or ocular hypertension
- Natural extension of their contact lens practice
- Comfortable fitting contact lenses

Mild/Moderate Patients

- No daily drops
- Continuous IOP reduction
- Help preserve sight

Current Progress

- ✓ Pre-IND meeting confirmed 505(b)(2) regulatory pathway
- ✓ GLP studies completed
- ✓ Phase 2a Clinical site and CRO secured
- ✓ GMP manufacturing for clinical lot completed & on stability
- ✓ IND ready to submit
- ✓ Phase 2a expected to start enrollment late Q4 2020

Lead Secured for Current Round

$2-3M

ROUND

Lead Secured

- $1.5M
- Leading Global Ophthalmic Pharmaceutical Company

Use of Funds

- IND Submission
- Phase 2a Clinical Study
- End of Phase 2 Meeting with FDA

$200k-$700k remains available in the round

Team – Proven Pharmaceutical & Ophthalmic Execution

Dan Myers
CEO

Founder of Alimera Sciences
Past President Novartis Ophthalmics
Over $250M raised
6 FDA drug approvals

Praful Doshi
Founder, CTO

40+ years in contact lenses,
510(k) approval, 30+ patents
17 years in digital printing

Kenny Key, *JD*
COO, General Counsel

Expert in regulatory law, finance and business strategy
8 years leading emerging growth companies

David Fancher
VP, Business Development

Past SVP of Sales, CooperVision,
Sales grew from $14M to $450M
Past Executive at Allergan and J&J

Orlando Rodrigues
VP, Commercial

30+ years experience in medical device and life science sectors. Key role in several acquisitions including $325M sale of I-Flow

Jill Healy
Trial Runners, CRO

CEO of Trial Runners, a leading ophthalmic CRO with several successful clinical trials

Martin Waters, *JD*
Wilson Sonsini, Corporate Counsel

Partner at Wilson Sonsini Goodrich & Rosati
20 years experience with emerging growth companies with several successful exits

Clinical & Regulatory Team

Jill Healy
Trial Runners, CRO

CEO of Trial Runners, a leading ophthalmic CRO with several successful clinical trials

Gary Novak, *PhD, PharmaLogic*
Regulatory Affairs, Pharmacology

25+ years experience in pharmaceutical R&D. Contributed to 40+ FDA approved products and over 100 IND/IDE submissions.



Ajit Simh, *Shiba Biotechnology*
Quality and Regulatory Compliance

15 years experience in drug development, CMC, GMP's, GLP, and GCP interpretation and application

P N Balasubramanian, *PhD*
Director, Quality Control

25 years experience in pharmaceutical QA/QC, cGMP compliance, and CMC supporting INDs and NDAs

Scientific Advisory Board

Constance Okeke, *MD, MSCE*

Glaucoma specialist at Virginia Eye Consultants. 20+ years of glaucoma experience. Glaucoma fellowship at Bascom Palmer Eye Institute

Houman Hemmati, *MD, PhD*

Adjunct Clinical Professor of Ophthalmology at the Keck School of Medicine at USC. Former Director of Clinical Development at Allergan.

Ian Benjamin Gaddie, *OD, FAAO*

Owner and director of Gaddie Eye Centers. President of the Optometric Glaucoma Society. Fellow of the American Academy of Optometry.

Mark Dunbar, *OD, FAAO*

Director of Optometric Services and Residency Supervisor Bascom Palmer Eye Institute.



Robert Davis, *OD, FAAO*

Director of Contact Lens Clinic. Co-Founder of Eye and Vision Research Institute.

Jo Ann Giaconi, *MD*

Glaucoma specialist at the UCLA Stein Eye Institute. Member of the American Glaucoma Society.

Walter Whitley, *OD, MBA, FAAO*

Director of optometric services at Virginia Eye Consultants. 20+ ophthalmic clinical trials.

Summary of Assets

IND Ready

GLP studies completed

CMO, CRO and site secured

Execution Team Secured

Patents Granted

US (8+) & OUS (15+)

Pipeline Established

Glaucoma, Dry Eye,

Comfort, Allergy…

LEO LENS™
PHARMA

Thank You

Questions?

Proud Member BIOCOM

CONNECT w/ SAN DIEGO VENTURE GROUP
COOL COMPANIES 2020
FOUNDING SPONSOR MINTZ | PERKINS COIE | MOSS ADAMS | COX BUSINESS | BDO

MOST INNOVATIVE
NEW PRODUCT AWARDS
Finalist

LaunchPad
SMALL BUSINESS DEVELOPMENT CENTER
Alumni Company

dmyers@leolens.com
www.leolens.com